NCT01010243 - Third-line Therapy of Multiple Myeloma a Prospective Phase I /II Trial | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2016

Conditions

Multiple Myeloma

Interventions

DRUG

Lenalidomide, Pioglitazone, dexamethasone, treosulfan

"Phase I:lenalidomide dose ( 5 mg or 10 mg or 15 mg) will be determined for phase II on the basis of DLTs in the first 4 weeks for the phase II part.~Start Phase I part: lenalidomide 10 mg p.o. daily + pioglitazone 60 mg p.o. daily + treosulfan 250 mg p.o. bid + dexamethasone initially 40 mg p.o. d1-4 and d15-18, then 20mg d1 and d15. dexamethasone 1 mg p.o. continuously within the intervals of pulsed dexamethasone therapy"

Trial Locations (6)

24105

RECRUITING

Universitätsklinikum Schleswig-Holstein, II Medizin, Sekt. f. Stammzell- u. Immuntherapie, Kiel

80336

RECRUITING

Klinikum d. Universität München, Med. Klinik u. Poliklinik IV, Abt. H/O, München

81241

RECRUITING

Gemeinschaftspraxis Hämato/Onkologie, München

82335

RECRUITING

Schön Klinik Starnberger See, Berg

90766

RECRUITING

Gemeinschaftspraxis Dres. med. J. Wilke u. H. Wagner, Fürth

93053

RECRUITING

University of Regensburg, Regensburg